Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Pre-Mkt 02-27 06:19:05 EST

13.52

+0.30

+2.27%

High13.67	Low12.67	Vol705.79K
Open13.06	D1 Closing13.22	Amplitude7.59%
Mkt Cap423.04M	Tradable Cap212.16M	Total Shares31.29M
T/O9.38M	T/O Rate4.50%	Tradable Shares15.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":13.52,"timestamp":1772139600000,"preClose":13.22,"halted":0,"volume":705790,"delay":0,"changeRate":0.02269288956127072,"floatShares":15692500,"shares":31289969,"eps":-2.10871,"marketStatus":"Pre-Mkt","change":0.3,"latestTime":"02-27 06:19:05 EST","open":13.06,"high":13.67,"low":12.6672,"amount":9377972.18221,"amplitude":0.075855,"askPrice":15.05,"askSize":100,"bidPrice":11.89,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.10871,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772202600000},"marketStatusCode":1,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":13.52,"postHourTrading":{"tag":"盘后","latestPrice":13.52,"preClose":13.52,"latestTime":"17:28 EST","volume":10825,"amount":146264.95,"timestamp":1772144934997,"change":0,"changeRate":0,"amplitude":0.013173},"volumeRatio":0.7605417012517682,"impliedVol":1.0126,"impliedVolPercentile":0.7613},"requestUrl":"/m/hq/s/LENZ","defaultTab":"news","newsList":[{"id":"2614183228","title":"Pelthos Therapeutics Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2614183228","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614183228?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:06","pubTimestamp":1772190360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTHS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2026 06:06 ET (11:06 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2614832153","title":"Structure Therapeutics price target lowered to $113 from $120 at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2614832153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614832153?lang=en_us&edition=fundamental","pubTime":"2026-02-27 18:55","pubTimestamp":1772189751,"startTime":"0","endTime":"0","summary":"Citizens analyst Jonathan Wolleben lowered the firm’s price target on Structure Therapeutics (GPCR) to $113 from $120 and keeps an Outperform ratin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-price-target-lowered-to-113-from-120-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-price-target-lowered-to-113-from-120-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2614178831","title":"Pelthos Therapeutics initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2614178831","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614178831?lang=en_us&edition=fundamental","pubTime":"2026-02-27 18:05","pubTimestamp":1772186751,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst David Amsellem initiated coverage of Pelthos Therapeutics (PTHS) with an Overweight rating and $48 price target The company’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pelthos-therapeutics-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pelthos-therapeutics-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2614838007","title":"Denali Therapeutics: Underappreciated Hunter Syndrome Launch and 2026 CNS Pipeline Catalysts Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614838007","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614838007?lang=en_us&edition=fundamental","pubTime":"2026-02-27 16:57","pubTimestamp":1772182623,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on DNLI stock, giving a Buy rating yesterday. Myles Minter has given his Buy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/denali-therapeutics-underappreciated-hunter-syndrome-launch-and-2026-cns-pipeline-catalysts-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/denali-therapeutics-underappreciated-hunter-syndrome-launch-and-2026-cns-pipeline-catalysts-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","CNS"],"gpt_icon":0},{"id":"2614887554","title":"Shield Therapeutics Updates Voting Rights as Iron Drug Expansion Continues","url":"https://stock-news.laohu8.com/highlight/detail?id=2614887554","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614887554?lang=en_us&edition=fundamental","pubTime":"2026-02-27 15:47","pubTimestamp":1772178473,"startTime":"0","endTime":"0","summary":"Shield Therapeutics ( ($GB:STX) ) has shared an announcement. Shield Therapeutics plc, a London-listed specialty pharmaceutical company, focuses on...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/shield-therapeutics-updates-voting-rights-as-iron-drug-expansion-continues?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/shield-therapeutics-updates-voting-rights-as-iron-drug-expansion-continues?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4539","BK4139"],"gpt_icon":0},{"id":"2614882509","title":"N4 Pharma Plans Rebrand to Thalia Therapeutics to Reflect RNA-Focused Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2614882509","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614882509?lang=en_us&edition=fundamental","pubTime":"2026-02-27 15:23","pubTimestamp":1772176984,"startTime":"0","endTime":"0","summary":"An update from N4 Pharma ( ($GB:N4P) ) is now available. N4 Pharma plc, the UK biotech behind the Nuvec gene delivery system for cancer and other a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/n4-pharma-plans-rebrand-to-thalia-therapeutics-to-reflect-rna-focused-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/n4-pharma-plans-rebrand-to-thalia-therapeutics-to-reflect-rna-focused-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","RNA","BK4505","IE0009354923.USD","LENZ","BK4585","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2614813708","title":"Nexalis Therapeutics Loss Widens as Net Tangible Assets Slide Further","url":"https://stock-news.laohu8.com/highlight/detail?id=2614813708","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614813708?lang=en_us&edition=fundamental","pubTime":"2026-02-27 14:58","pubTimestamp":1772175482,"startTime":"0","endTime":"0","summary":"InhaleRx Limited ( ($AU:NX1) ) just unveiled an update. Nexalis Therapeutics Ltd has reported a significant widening of its annual loss, with the d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nexalis-therapeutics-loss-widens-as-net-tangible-assets-slide-further?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nexalis-therapeutics-loss-widens-as-net-tangible-assets-slide-further?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"2614883742","title":"Chimeric Therapeutics Posts Wider Half-Year Loss as Auditor Flags Going Concern Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2614883742","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614883742?lang=en_us&edition=fundamental","pubTime":"2026-02-27 13:37","pubTimestamp":1772170674,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Chimeric Therapeutics Ltd. ( ($AU:CHM) ). Chimeric Therapeutics Limited reported a sharp increase in its half-y...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chimeric-therapeutics-posts-wider-half-year-loss-as-auditor-flags-going-concern-risk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chimeric-therapeutics-posts-wider-half-year-loss-as-auditor-flags-going-concern-risk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2614704520","title":"PYC Therapeutics Advances Polycystic Kidney Disease Drug Candidate to Next Dose Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2614704520","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614704520?lang=en_us&edition=fundamental","pubTime":"2026-02-27 07:24","pubTimestamp":1772148274,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  said that its safety review committee has approved dose escalation to cohort B3 in the ongoing single ascending dose  trial of PYC-003, following a review of four-week safety data from polycystic kidney disease  patients in cohorts B1 and B2, according to a Friday Australian bourse filing.The trial primarily evaluates safety and tolerability, with efficacy as a secondary endpoint, and if successful, will support initiation of a combined phase 2/3 registrational study toward a new drug application for PYC-003, the filing added.PYC-003 drug candidate is designed to address and treat the underlying cause of PKD, per the filing.The SAD study will subsequently transition into an open-label multiple ascending dose phase to evaluate repeat dosing and establish the optimal treatment regimen, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK7047","PKD.AU","LENZ","PYC.AU","PKD","BK4007","BK4139","BK7067"],"gpt_icon":0},{"id":"2614077258","title":"Eterna Therapeutics Updates Investor Presentation, Highlights Web Disclosure","url":"https://stock-news.laohu8.com/highlight/detail?id=2614077258","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614077258?lang=en_us&edition=fundamental","pubTime":"2026-02-27 06:51","pubTimestamp":1772146296,"startTime":"0","endTime":"0","summary":"Eterna Therapeutics ( ($ERNA) ) has provided an announcement. On February 26, 2026, Ernexa Therapeutics Inc. released an updated investor presentat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eterna-therapeutics-updates-investor-presentation-highlights-web-disclosure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eterna-therapeutics-updates-investor-presentation-highlights-web-disclosure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2614485074","title":"Denali Therapeutics Q4 EPS $(0.73) Beats $(0.76) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614485074","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614485074?lang=en_us&edition=fundamental","pubTime":"2026-02-27 06:06","pubTimestamp":1772143587,"startTime":"0","endTime":"0","summary":"Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.76) by 4.45 percent. This is a 8.96 percent decrease over losses of $(0.67) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50915323/denali-therapeutics-q4-eps-0-73-beats-0-76-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Denali Therapeutics Q4 EPS $(0.73) Beats $(0.76) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2614746400","title":"Keros Therapeutics Adds Veteran Finance Leader to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2614746400","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614746400?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:54","pubTimestamp":1772142870,"startTime":"0","endTime":"0","summary":"Keros Therapeutics ( ($KROS) ) has shared an announcement. On February 24, 2026, Keros Therapeutics’ board appointed former Lyell Immunopharma CFO ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/keros-therapeutics-adds-veteran-finance-leader-to-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/keros-therapeutics-adds-veteran-finance-leader-to-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","KROS","LENZ","BK4505","LYEL","BK4139"],"gpt_icon":0},{"id":"2614071530","title":"Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614071530","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614071530?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:05","pubTimestamp":1772139900,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., Feb.  26, 2026  (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and rela","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3246086/0/en/Mineralys-Therapeutics-Reports-Inducement-Awards-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2614076836","title":"Press Release: Keros Therapeutics Appoints Charles Newton to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2614076836","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614076836?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:01","pubTimestamp":1772139660,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., Feb. 26, 2026  -- Keros Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta  family of proteins, today announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026.\"We are pleased to welcome Mr. Newton to Keros' Board of Directors,\" said Jean-Jacques Bienaimé, Chair of the Board of Directors. \"His extensive expertise in healthcare finance and capital markets, coupled with his track record of helping companies navigate through key value inflection points in their clinical programs, will be highly complementary to the Board's existing skillsets. As we continue to advance our pipeline, his perspective will be invaluable in supporting disciplined execution and positioning the Company for long-term growth and value creation.\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4007","BK4139","LENZ","BK4539"],"gpt_icon":0},{"id":"2614007350","title":"Mineralys Therapeutics Inc options imply 16.5% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2614007350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614007350?lang=en_us&edition=fundamental","pubTime":"2026-02-27 04:16","pubTimestamp":1772137019,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in Mineralys Therapeutics (MLYS) Inc is 28.3x normal with puts leading calls 2:1. Implied volatility suggests the marke...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mineralys-therapeutics-inc-options-imply-16-5-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mineralys-therapeutics-inc-options-imply-16-5-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2614002089","title":"Tango Therapeutics weakness an ‘over reaction,’ says Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2614002089","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614002089?lang=en_us&edition=fundamental","pubTime":"2026-02-27 02:28","pubTimestamp":1772130483,"startTime":"0","endTime":"0","summary":"Stifel believes Tango Therapeutics (TNGX) shares are reacting in large part due to Revolution Medicines’ (RVMD) announcement of a clinical trial co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tango-therapeutics-weakness-an-over-reaction-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tango-therapeutics-weakness-an-over-reaction-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SF","BK4539","LENZ","BK4127","RVMD","BK4007","TNGX"],"gpt_icon":0},{"id":"2614802280","title":"Pelthos Therapeutics Is Maintained at Buy by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2614802280","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614802280?lang=en_us&edition=fundamental","pubTime":"2026-02-27 01:37","pubTimestamp":1772127420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTHS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2026 12:37 ET (17:37 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2614029402","title":"Wedbush Cuts Viridian Therapeutics Price Target to $44 From $47, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614029402","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614029402?lang=en_us&edition=fundamental","pubTime":"2026-02-27 00:20","pubTimestamp":1772122820,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics (VRDN) has an average rating of buy and mean price target of $41.44, according to analysts polled by FactSet.Price: 29.24, Change: +0.29, Percent Change: +1.02","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"gpt_icon":0},{"id":"2614040183","title":"Press Release: Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2614040183","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614040183?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:10","pubTimestamp":1772115000,"startTime":"0","endTime":"0","summary":"TAMPA, Fla. and LONDON, Feb. 26, 2026  -- Akari Therapeutics, Plc , an oncology biotechnology company developing antibody drug conjugates  with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board.\"Dr. Gokhale's expertise in experimental therapeutics, RNA biology and translational oncology comes at a pivotal time as we advance AKTX-101 toward the clinic,\" commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. \"His proven track record to develop novel translational experiments/data that lead to well-designed and high-impact clinical strategies will strengthen our development approach as we advance AKTX-101 to clinical trials. As we move closer to first-in-human studies, his insight will help ensure that AKTX-101 and our novel PH1 spliceosome-modulating payload enter the clinic with a f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","LENZ","BK4007","BK4539","BK4588","IE0009354923.USD","BK4585","AKTX","RNA"],"gpt_icon":0},{"id":"2614888049","title":"Viridian Therapeutics Q4 EPS $(1.08) Misses $(0.93) Estimate, Sales $132.000K","url":"https://stock-news.laohu8.com/highlight/detail?id=2614888049","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614888049?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:23","pubTimestamp":1772108581,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.93) by 16.76 percent. This is a 33.33 percent decrease over losses of $(0.81) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50883210/viridian-therapeutics-q4-eps-1-08-misses-0-93-estimate-sales-132-000k","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.graphitebio.com","stockEarnings":[{"period":"1week","weight":0.122},{"period":"1month","weight":-0.3027},{"period":"3month","weight":-0.557},{"period":"6month","weight":-0.65},{"period":"1year","weight":-0.3849},{"period":"ytd","weight":-0.155}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032855},{"month":3,"riseRate":0.25,"avgChangeRate":-0.098838},{"month":4,"riseRate":0.5,"avgChangeRate":-0.02248},{"month":5,"riseRate":0.25,"avgChangeRate":-0.134416},{"month":6,"riseRate":0.75,"avgChangeRate":0.05507},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}